Summary & Overview
HCPCS S3861: SCN5A Genetic Testing for Suspected Brugada Syndrome
HCPCS Level II code S3861 denotes genetic testing for the SCN5A gene and its variants in patients with suspected Brugada syndrome. This molecular diagnostic service identifies variants in the cardiac sodium channel alpha subunit that can inform diagnosis, risk stratification, and family testing for inherited arrhythmia disorders. Because SCN5A pathogenic variants are clinically actionable, coverage and coding clarity for S3861 affect diagnostic pathways, care coordination, and downstream utilization of cardiac services.
Key payers in the national context include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of payer coverage patterns, coding and billing considerations, and relevant clinical context for ordering SCN5A testing. The publication presents benchmarks for utilization and reimbursement where available, summarizes policy updates that impact genetic testing coverage, and situates S3861 within diagnostic workflows for inherited arrhythmia evaluation. Clinical implications covered include the role of SCN5A testing in confirming Brugada syndrome, informing cascade testing of relatives, and integrating genetic results with electrophysiologic and imaging assessments.
Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code S3861 describes genetic testing for the SCN5A gene (sodium channel, voltage-gated, type V, alpha subunit) and variants for patients with suspected Brugada syndrome. The service consists of molecular diagnostic testing to identify pathogenic variants in the SCN5A gene that are associated with inherited cardiac arrhythmia and sudden cardiac death risk.
-
Service type: Genetic testing / molecular diagnostic testing
-
Typical site of service: Clinical diagnostic laboratory or outpatient specimen collection site
Clinical & Coding Specifications
Clinical Context
A 32-year-old patient presents to a cardiac genetics clinic after a syncopal event and a family history of sudden cardiac death. The ECG shows a type 1 Brugada pattern, and the cardiologist suspects Brugada syndrome. The clinician orders genetic testing targeting the SCN5A gene (S3861) to identify pathogenic variants that inform diagnosis, risk stratification, and family cascade testing. Specimen collection is typically peripheral blood or saliva, obtained in an outpatient clinic or ambulatory genetics laboratory. The sample is sent to a molecular diagnostics laboratory for sequencing and variant interpretation. Results are reported to the ordering cardiologist and genetic counselor; positive findings prompt counseling, consideration of implantable cardioverter-defibrillator (ICD) candidacy, and cascade testing of relatives. Typical sites of service include outpatient cardiology or genetics clinics, hospital outpatient departments, and certified molecular diagnostic laboratories.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when billing separately for the physician interpretation of genetic test results when the laboratory bills technical component. |
52 |